Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free SXTC Stock Alerts

China SXT Pharmaceuticals (SXTC) Competitors

China SXT Pharmaceuticals logo
$0.07 -0.06 (-45.57%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$0.06 -0.01 (-12.69%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SXTC vs. OBSV, TRIB, NKGN, APRE, and MTVA

Should you buy China SXT Pharmaceuticals stock or one of its competitors? MarketBeat compares China SXT Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China SXT Pharmaceuticals include ObsEva (OBSV), Trinity Biotech (TRIB), NKGen Biotech (NKGN), Aprea Therapeutics (APRE), and MetaVia (MTVA).

How does China SXT Pharmaceuticals compare to ObsEva?

China SXT Pharmaceuticals (NASDAQ:SXTC) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

China SXT Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

China SXT Pharmaceuticals has higher revenue and earnings than ObsEva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M2.25-$6.20MN/AN/A
ObsEvaN/AN/A-$58.38M-$0.92N/A

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for ObsEva. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
ObsEva Neutral

Given ObsEva's higher probable upside, analysts plainly believe ObsEva is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

China SXT Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
ObsEva N/A -416.36%-92.01%

Summary

China SXT Pharmaceuticals beats ObsEva on 7 of the 10 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Trinity Biotech?

Trinity Biotech (NASDAQ:TRIB) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trinity Biotech Neutral
China SXT Pharmaceuticals Neutral

China SXT Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-70.06% N/A -32.13%
China SXT Pharmaceuticals N/A N/A N/A

China SXT Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.17-$37.38M-$44.26N/A
China SXT Pharmaceuticals$1.14M2.25-$6.20MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

China SXT Pharmaceuticals beats Trinity Biotech on 5 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to NKGen Biotech?

China SXT Pharmaceuticals (NASDAQ:SXTC) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
NKGen Biotech N/A N/A -479.36%

China SXT Pharmaceuticals has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M2.25-$6.20MN/AN/A
NKGen BiotechN/AN/A-$82.94M-$1.68N/A

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

China SXT Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for NKGen Biotech. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
NKGen Biotech Neutral

Summary

China SXT Pharmaceuticals beats NKGen Biotech on 6 of the 8 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. China SXT Pharmaceuticals' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aprea Therapeutics-4,405.59% -61.03% -50.24%
China SXT Pharmaceuticals N/A N/A N/A

Aprea Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

China SXT Pharmaceuticals has higher revenue and earnings than Aprea Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aprea Therapeutics$290K26.51-$12.60M-$1.54N/A
China SXT Pharmaceuticals$1.14M2.25-$6.20MN/AN/A

Aprea Therapeutics presently has a consensus price target of $4.07, indicating a potential upside of 554.86%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aprea Therapeutics is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aprea Therapeutics had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 3 mentions for Aprea Therapeutics and 1 mentions for China SXT Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
China SXT Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Aprea Therapeutics beats China SXT Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to MetaVia?

China SXT Pharmaceuticals (NASDAQ:SXTC) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 1 articles in the media. China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled MetaVia'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
China SXT Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MetaVia
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

China SXT Pharmaceuticals' return on equity of 0.00% beat MetaVia's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
MetaVia N/A -172.92%-89.39%

China SXT Pharmaceuticals has higher revenue and earnings than MetaVia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M2.25-$6.20MN/AN/A
MetaViaN/AN/A-$12.97M-$5.19N/A

China SXT Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,242.28%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MetaVia
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

China SXT Pharmaceuticals beats MetaVia on 7 of the 10 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTC vs. The Competition

Export
MetricChina SXT PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.71M$11.55B$6.86B$12.98B
Dividend YieldN/A2.73%2.60%9.79%
P/E RatioN/A788.92280.4025.25
Price / Sales2.25747.24562.1377.61
Price / CashN/A72.4271.7950.79
Price / Book0.0010.8612.946.09
Net Income-$6.20M$2.82B$3.49B$347.95M
7 Day PerformanceN/A2.43%2.42%3.11%
1 Month PerformanceN/A-1.71%-2.87%-2.99%
1 Year PerformanceN/A195.53%75.29%20.51%

China SXT Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTC
China SXT Pharmaceuticals
0.7922 of 5 stars		$0.07
-45.6%		N/A-100.0%$4.71M$1.14MN/A90
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/AN/A50
TRIB
Trinity Biotech
0.5307 of 5 stars		$13.18
+5.9%		N/A-60.3%$7.91M$43.78MN/A480
NKGN
NKGen Biotech
N/A$0.06
flat		N/A-97.0%$7.84MN/AN/AN/A
APRE
Aprea Therapeutics
3.2856 of 5 stars		$0.62
+1.2%		$4.07
+554.9%		-65.3%$7.69M$290KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Palantir’s 1,540% vs 32,481% company no one’s talking about
Palantir investors who bought at IPO are sitting on gains near 1540%. But Mode Mobile, still private, has alre...
Mode Mobile | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...
Stansberry Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel